

8th February 2017

Dr D Jeyaseelan
Child Development Unit
WCHN

Research Secretariat
Level 2, Samuel Way Building
72 King William Road
North Adelaide SA 5006
Tel 08 8161 6390
Tel 08 8161 6521
www.wch.sa.gov.au

Dear Dr Jeyaseelan

Re: The ASQ-TRAK developmental screening tool for Australian Aboriginal children. Determining the reliability and face validity of the ASQ TRAK and exploring the characteristics of developmental difficulties in Aboriginal children in urban, regional and remote South Australia. HREC/16/WCHN/185. Ethics expiry date: 28/2/20

**Lead HREC for the above study for the following institutions/sites:
Women's and Children's Health Network**

I refer to your letter dated 22nd December 2016 in which you responded to matters raised by the WCHN Human Research Ethics Committee at its December 2016 meeting. I am pleased to advise that your protocol has been granted full ethics approval and meets the requirements of the *National Statement on Ethical Conduct in Human Research*.

Specifically, the following documents have been noted/approved:

<i>Document</i>	<i>Version</i>	<i>Date</i>
NEAF Application	Au/1/8b5a25	23 November 2016
Plain language statement - parent/caregiver/guardian	3	25 July 2016
Information sheet - parent/caregiver/guardian	1.1	21 December 2016
Consent Form – parent/caregiver/guardian	1.0	22 November 2016
Flow chart	1.0	22 November 2016
Staff information sheet	1.0	22 December 2016
Response to AHREC		22 December 2016
Questionnaire – CaFHS staff	1.0	22 November 2016
Questionnaire/s: ASQ-TRAK for 18 months – personal social domain	3	

This letter constitutes advice on ethical consideration only. You must not commence this research project at a site until you have obtained separate research governance approval from the site concerned. A copy of this letter should be forwarded to all site investigators for submission to the relevant Research Governance Officer.

At the WCHN, or any other SA Health site, separate authorisation from the Chief Executive or delegate of that site must be obtained through a Site Specific Assessment (SSA) request. For information on this process at the WCHN, please contact the WCHN Research Governance Officer, Ms Camilla Liddy (telephone 8161 6688, email camilla.liddy@sa.gov.au).

I remind you approval is given subject to:


- immediate notification of any serious or unexpected adverse events to participants;
- immediate notification of any unforeseen events that might affect continued ethical acceptability of the project;



- submission of any proposed changes to the original protocol. Changes must be approved by the Committee before they are implemented;
- immediate advice, giving reasons, if the protocol is discontinued before its completion;
- submission of an annual report on the progress of the study, and a final report when it is completed to the WCHN Research Governance Officer. It is your responsibility to provide these reports, without reminder. The proforma for the report may be found on the WCHN Research Governance and Ethics website.

Approval is given for three years only. If the study is more prolonged than this, an extension request should be submitted unless there are significant modifications, in which case a new submission may be required. Please note the expiry date in the title above and include it in any future communications.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Tamara Zutlevics', written in a cursive style.

TAMARA ZUTLEVICS (DR)
CHAIR
WCHN HUMAN RESEARCH ETHICS COMMITTEE

WOMEN'S AND CHILDRENS HEALTH NETWORK (WCHN)
HUMAN RESEARCH ETHICS COMMITTEE (HREC)

REGISTERING OF CLINICAL TRIALS

The WCHN Human Research Ethics Committee (HREC) and Drug and Therapeutics Committee Clinical Trials Group (DTC) would like to draw researcher's attention to a joint editorial issued by members of the International Committee of Medical Journal Editors (ICMJE) which appeared in *The New England Journal of Medicine* June 9, 2005. ICMJE members stated that,

In September 2004, the members of the International Committee of Medical Journal Editors (ICMJE) published a joint editorial aimed at promoting registration of all clinical trials. We stated that we will consider a trial for publication only if it has been registered before the enrolment of the first patient. This policy applies to trials that start recruiting on or after July 1, 2005.

For further information regarding the registering of trials researchers are directed to the above mentioned editorial – <http://content.nejm.org/cgi/reprint/352/23/2436.pdf>

In Australia, the National Health Medical Research Committee has set up the Australian Clinical Trials Registry (ACTR) which researchers can access. It is a national online register of clinical trials being undertaken in Australia. The ACTR includes trials from the full spectrum of therapeutic areas. It has nationwide coverage of all clinical trials involving Australian researchers or Australian participants. General information on the registry can be found at <http://www.actr.org.au>

Any project that prospectively assigns human participants to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome (ICMJE definition) should be registered, including early phase uncontrolled trials (phase I) in patients or healthy volunteers (WHO Recommendation). If in doubt, registration is recommended. The REC is unable to register clinical trials. Consequently, those researchers seeking to register their trials will need to do so themselves.

Please bring this notice to the attention of all researchers and potential researchers in your department.

In keeping with the above, it is a WCHN HREC requirement for trials to be registered before enrolment of the first patient.

Newsletter Issue 2, Dec 2006 for the Registry may be accessed at <http://actr.org.au/docs/ACTRNewsletterIssue221Dec06.pdf>